PETACH TIKVA, Israel, March 14, 2013 -- /PRNewswire/ --Macrocure (http://www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that the European Patent Office (EPO) intends to grant a European patent covering Marcocure's flagship product, CureXcell®. The patent will be officially granted under an application titled "Activate Leukocyte Composition" and will provide patent coverage for CureXcell® in Europe through March 2030.
CureXcell® is a novel approach to treating hard-to-heal wounds by replenishing the imbalanced inflammatory environment in non-healing wounds with a broad array of functionally-active allogeneic immune cells. These cells are superficially injected into the wound bed, once a month, and release the necessary cytokines and growth factors for the wound to heal.
About 5,000 patients with various types and severities of hard-to-heal wounds have been treated in Israel. CureXcell® has been approved for reimbursement by the Israeli Ministry of Health.
"The granting of a European patent for CureXcell® is a significant milestone for MacroCure, which fits with our strategy to become a leader in the hard to heal wound treatment market in Europe," said Nissim Mashiach, President and CEO of Macrocure.
Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies. Macrocure is pursuing regulatory market approval in North America and Europe. CureXcell® is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes under SPA in the United States, Canada and Israel. The product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.
Matthew Krieger Finn Partners Israel for Macrocure +972-544-676-950 email@example.com